Related Experiment Video
Updated: Jul 8, 2026
An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
[Contrast sensitivity in diabetic retinopathy treated with argon laser panphotocoagulation]
Otacílio de Oliveira Maia1, Walter Yukihiko Takahashi, Marcos Wilson Sampaio
1Faculdade de Medicina, Universidade de São Paulo, and Departamento de Oftalmologia do Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, SP, Brazil. omaiausp@uol.com.br
Purpose:
To evaluate contrast sensitivity in patients with diabetic retinopathy (DR) treated with argon laser panphotocoagulation.
Methods:
Prospective study of patients with diabetic retinopathy and 20/20 visual acuity, treated with retinal panphotocoagulation, following ETDRS criteria. The patients were submitted, initially, to complete ophthalmologic evaluation and contrast sensitivity testing (Vision Contrast Test System). After 3 months of treatment, they were reevaluated by means of visual acuity and contrast sensitivity.
Results:
The sample comprised 28 patients (28 eyes), all with type II diabetes. A ranged from 45 to 77 years (mean 57.8+/-8.0), 19 (67.9%) patients were male and 9 (32.1%) female. Regarding the type of retinopathy, 18 (64.3%) had proliferative DR and 10 (35.7%) very severe non proliferative RD. No visual acuity alteration was observed after treatment. In relation to contrast sensitivity, there were no alterations between pre and post-treatment in all evaluated spacial frequencies 1.5 (p=0.191); 3.0 (p=0.850); 6.0 (p=0.374); 12.0 (p=0.674) e 18.0 (p=0.443).
Conclusion:
There was no significant alteration in the contrast sensitivity of patients with diabetic retinopathy after panphotocoagulation with argon laser in the studied period.
